Pharmaceutical

Risk adjusted net present value: What is the current valuation of AstraZeneca’s Rilvegostomig?

Rilvegostomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Bile Duct Cancer (Cholangiocarcinoma).

Mar 13, 2024 - 18:29
Rilvegostomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Bile Duct Cancer (Cholangiocarcinoma).
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Novo Nordisk’s...

Next Article

Risk adjusted net present value: What is the current valuation of Novo Nordisk’s...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Cannabidiol milling: Selecting the right equipment for CBD testing

Cannabidiol milling: Selecting the right equipment for ...

Mar 21, 2023

STAT+: Annexon’s trial of an eye disease drug missed by a mile. The company saw a bull’s eye

STAT+: Annexon’s trial of an eye disease drug missed by...

May 25, 2023

Bristol Myers Squibb reports 6% drop in Q2 2023 revenues

Bristol Myers Squibb reports 6% drop in Q2 2023 revenues

Jul 29, 2023